
June 19, 2025
Uniquely engineered KRAS-targeted cancer drug found to be effective in early studies
Chad Pecot, MD, and colleagues have demonstrated that a uniquely engineered drug that zeroes in on a mutated gene called KRAS G12V could potentially stop KRAS-dependent cancers in their tracks.